Citation: | FENG Dan-dan, GENG Jing-jing, XU Liang, YUAN Hui. Rationality evaluation of predisone dosage in the treatement of SLE with different clinical scoring systems[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(3): 332-335. doi: 10.16462/j.cnki.zhjbkz.2019.03.018 |
[1] |
Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus[J]. Lancet, 2014, 384(9957): 1878-1888. DOI: 10.1016/S0140-6736(14)60128-8.
|
[2] |
Singh JA, Hossain A, Kotb A, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis[J]. BMC Med, 2016, 14(1): 137. DOI: 10.1186/s12916-016-0673-8.
|
[3] |
Hay E, Gordon C, Emery P. Assessment of lupus: where are we now?[J]. Ann Rheum Dis, 1993, 52(3): 169-172. doi: 10.1136/ard.52.3.169
|
[4] |
Tsutsumi A, Ichikawa K, Atsumi T, et al. Use of various methods for anticardiolipin detection in the updated American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: comment on the letter by Hochberg[J]. Arthritis Rheum, 2010, 41(7): 1326-1327. DOI:10.1002/1529-0131(199807)41:7<1326::AID-ART29>3.0.CO;2-4.
|
[5] |
Cook RJ, Gladman DD, Pericak D, et al. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity[J]. J Rheumatol, 2000, 27(8): 1892-1895. http://www.ncbi.nlm.nih.gov/pubmed/10955329
|
[6] |
Bae SC, Koh HK, Chang D K, et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus[J]. Lupus, 2001, 10(6): 405-409. DOI: 10.1191/096120301678646146.
|
[7] |
系统性红斑狼疮诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(5): 342-346.
Guidelines for the diagnosis and treatment of systemic lupus erythematosus[J]. Chin J Rheumatol, 2010, 14(5): 342-346.
|
[8] |
Chang E, Abrahamowicz M, Ferland D, et al. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians[J]. J Clin Epidemiol, 2002, 55(5): 488-497. doi: 10.1016/S0895-4356(01)00509-1
|
[9] |
Fatemi A, Raeisi A, Sayedbonakdar Z. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study[J]. Clin Rheumatol, 2018, 37(4): 955-962. DOI: 10.1007/s10067-017-3949-2.
|
[10] |
萧健萍, 周强, 张森, 等. 可诱导共刺激分子配体在系统性红斑狼疮血清中水平及临床意义[J]. 中华疾病控制杂志, 2016, 20(10): 999-1003. DOI: 10.16462/j.cnki.zhjbkz.2016.10.008.
Xiao JP, Zhou Q, Zhang S, et al. Serum levels and clinical significance of soluble ICOSL in patients with systemic lupus erythematosus[J]. Chin J Dis Control Prev, 2016, 20(10): 999-1003. DOI: 10.16462/j.cnki.zhjbkz.2016.10.008.
|
[11] |
Vollenhoven RFV, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force[J]. Ann Rheum Dis, 2014, 73(6): 958-967. DOI: 10.1136/annrheumdis-2013-205139.
|
[12] |
Hahn BH, Mcmahon M A, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis[J]. Arthritis Care Res(Hoboken), 2012, 64(6): 797-808. DOI: 10.1002/acr.21664.
|
[13] |
Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus[J]. J Rheumatol, 2000, 27(3): 664-670. http://europepmc.org/abstract/MED/10743805
|
[14] |
Yee CS, Cresswell L, Farewell V, et al. Numerical scoring for the BILAG-2004 index[J]. Rheumatology, 2010, 49(9): 1665. DOI: 10.1093/rheumatology/keq026.
|
[15] |
Chang E, Abrahamowicz M, Ferland D, et al. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians[J]. J ClinEpidemiol, 2002, 55(5): 488-497. http://www.ncbi.nlm.nih.gov/pubmed/12007552
|